Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes

Nayyar Iqbal1 Bristol-Myers Squibb, Princeton, NJ, USACorrespondence[email protected]

Elsie Allen1 Bristol-Myers Squibb, Princeton, NJ, USA

Peter Öhman2 AstraZeneca, Wilmington, DE, USA

Pages 1479-1487 | Published online: 04 Sep 2014

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

Centers for Disease Control and PreventionNational diabetes statistics report: estimates of diabetes and its burden in the United States2014 Available from: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdfAccessed June 11, 2014
Google Scholar
BrownAFMangioneCMSalibaDSarkisianCAGuidelines for improving the care of the older person with diabetes mellitusJ Am Geriatr Soc200351Suppl 5S265S28012694461
PubMed Web of Science ®Google Scholar
KirkmanMSBriscoeVJClarkNDiabetes in older adults: a consensus reportJ Am Geriatr Soc2012602342235623106132
PubMed Web of Science ®Google Scholar
InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care2012351364137922517736
PubMed Web of Science ®Google Scholar
PaolissoGPathophysiology of diabetes in elderly peopleActa Biomed201081Suppl 1475320518191
PubMedGoogle Scholar
KyrouITsigosCObesity in the elderly diabetic patient: is weight loss beneficial? NoDiabetes Care200932Suppl 2S403S40919875589
PubMed Web of Science ®Google Scholar
SchwartzSLTreatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitorsAm J Geriatr Pharmacother2010840541821335294
PubMed Web of Science ®Google Scholar
SuhDCKimCMChoiISPlauschinatCAComorbid conditions and glycemic control in elderly patients with type 2 diabetes mellitus, 1988 to 1994 to 1999 to 2004J Am Geriatr Soc20085648449218179506
PubMed Web of Science ®Google Scholar
Onglyza^® (saxagliptin)Princeton, NJ/Wilmington, DE, USABristol-Myers Squibb/AstraZeneca Pharmaceuticals LP2011
Google Scholar
CharbonnelBCariouBPharmacological management of type 2 diabetes: the potential of incretin-based therapiesDiabetes Obes Metab2011139911721199262
PubMed Web of Science ®Google Scholar
DeFronzoRAHissaMNGarberAJThe efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin aloneDiabetes Care2009321649165519478198
PubMed Web of Science ®Google Scholar
HollanderPLiJAllenEChenRCV181-013 InvestigatorsSaxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione aloneJ Clin Endocrinol Metab2009944810481919864452
PubMed Web of Science ®Google Scholar
ChacraARTanGHApanovitchARavichandranSListJChenRSaxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trialInt J Clin Pract2009631395140619614786
PubMed Web of Science ®Google Scholar
BarnettAHCharbonnelBDonovanMFlemingDEffect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metforminCurr Med Res Opin20122851352322313154
PubMed Web of Science ®Google Scholar
ChacraARTanGHRavichandranSListJChenRCV181040 InvestigatorsSafety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeksDiab Vasc Dis Res2011815015921562067
PubMed Web of Science ®Google Scholar
HollanderPLLiJFrederichRAllenEChenRCV181040 InvestigatorsSafety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitusDiab Vasc Dis Res2011812513521562064
PubMed Web of Science ®Google Scholar
RosenstockJGrossJLAguilar-SalinasCLong-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with type 2 diabetesDiabet Med2013301472147623802840
PubMed Web of Science ®Google Scholar
DoucetJChacraAMaheuxPLuJHarrisSRosenstockJEfficacy and safety of saxagliptin in older patients with type 2 diabetes mellitusCurr Med Res Opin20112786386921323504
PubMed Web of Science ®Google Scholar
KaryekarCSRavichandranSAllenEFlemingDFrederichRTolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥65 years) with inadequately controlled type 2 diabetes mellitusClin Interv Aging2013841943023626461
PubMed Web of Science ®Google Scholar
DeFronzoRAHissaMNGarberAJThe efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin aloneDiabetes Care2009321649165519478198
PubMed Web of Science ®Google Scholar
SchernthanerGBarnettAHEmserASafety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3,572 patients with type 2 diabetes mellitusDiabetes Obes Metab20121447047822268497
PubMed Web of Science ®Google Scholar
HornickTAronDCManaging diabetes in the elderly: go easy, individualizeCleve Clin J Med200875707818236732
PubMed Web of Science ®Google Scholar
American Diabetes AssociationStandards of medical care in diabetes – 2012Diabetes Care201235Suppl 1S11S6322187469
PubMed Web of Science ®Google Scholar
BarzilaiNGuoHMahoneyEMEfficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trialCurr Med Res Opin2011271049105821428727
PubMed Web of Science ®Google Scholar
SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med20133691317132623992601
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date